ArticleMolecules (Basel, Switzerland)2022
Formulation, Optimization, and Evaluation of
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the Therapeutic Benefits ofCurrent drug research reviews · 2026Review
- Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.Current pharmaceutical design · 2026Review
- Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Exploring the potential of Moringa oleifera seed extract-loaded microemulsion hydrogel in the DNCB-induced atopic dermatitis model.Inflammopharmacology · 2025Article
- Integrating Quality by Design (QbD) in Phytosomal Drug Delivery: A New Era in Precision Phytotherapy.AAPS PharmSciTech · 2025Review
- Moringa oil-based nanocarrier system containing curcumin formulation as anti-breast cancer agent: Efficacy and safety study.Narra J · 2025Article
- A Narrative Review on Plant Extracts for Metabolic Syndrome: Efficacy, Safety, and Technological Advances.Nutrients · 2025Review
- Phytosomes Nanocarrier with Insight Towards the Future in Cancer Therapy: A Mini-Review.Pharmaceutical nanotechnology · 2025Review
- Phytosome-Enhanced Secondary Metabolites for Improved Anticancer Efficacy: Mechanisms and Bioavailability Review.Drug design, development and therapy · 2025Review
- Phytosomes-Unraveling the Unique Properties of Plant-Derived Nanotechnological Drug Delivery Systems: A Review.Current medicinal chemistry · 2025Review
- Harnessing Polyphenols and Novel Delivery Strategies for Effective Treatment of Breast Cancer.Recent advances in drug delivery and formulation · 2025Review
- Green synthesis of Brassica carinata microgreen silver nanoparticles, characterization, safety assessment, and antimicrobial activities.Scientific reports · 2024Article
- Preparing a Phytosome for Promoting Delivery Efficiency and Biological Activities of Methyl Jasmonate-TreatedBiomolecules · 2024Article
- Newly synthesized chitosan nanoparticles loaded with caffeine/moringa leaf extracts Halt Her2, BRCA1, and BRCA2 expressions.Scientific reports · 2024Article
- Review
- Review
- Advanced Delivery System of Polyphenols for Effective Cancer Prevention and Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- Formulation of Phytosomes with Extracts of Ginger Rhizomes and Rosehips with Improved Bioavailability, Antioxidant and Anti-Inflammatory Effects In Vivo.Pharmaceutics · 2023Article
- Biopolymer- and Lipid-Based Carriers for the Delivery of Plant-Based Ingredients.Pharmaceutics · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moringa oleifera leaf polyphenols (Mopp) were encapsulated with phytosomes to enhance their efficacy on 4T1 cancer cell lines. The Mopp were extracted via microwave-assisted extraction. Moringa oleifera polyphenol-loaded phytosomes (MoP) were prepared with the nanoprecipitation method and characterized using the dynamic light scattering and dialysis membrane techniques. The in vitro cytotoxic and antiproliferative activity were investigated with the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazole) MTT assay. Acute toxicity was assessed using Swiss albino mice. An MoP particle size of 296 ± 0.29 nm, −40.1 ± 1.19 mV zeta potential, and polydispersity index of 0.106 ± 0.002 were obtained. The total phenolic content was 50.81 ± 0.02 mg GAE/g, while encapsulation efficiency was 90.32 ± 0.11%. The drug release profiles demonstrated biphasic and prolonged subsequent sustained release. In vitro assays indicated MoP had a low cytotoxicity effect of 98.84 ± 0.53 μg/mL, doxorubicin was 68.35 ± 3.508, and Mopp was 212.9 ± 1.30 μg/mL. Moreover, MoP exhibited the highest antiproliferative effect on 4T1 cancer cells with an inhibitory concentration of 7.73 ± 2.87 μg/mL and selectivity index > 3. The results indicated a significant difference (p ≤ 0.001) in MoP when compared to Mopp and doxorubicin. The in vivo investigation showed the safety of MoP at a dose below 2000 mg/kg. The present findings suggest that MoP may serve as an effective and promising formulation for breast cancer drug delivery and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.